Tirzepatide (Zepbound): A separate GLP-1/GIP dual agonist with comparable or superior efficacy in SURMOUNT-1 (N=2,539, 72 weeks: 20.9% mean weight loss at 15 mg) [15], and potentially different insurance coverage depending on your plan In SURMOUNT-1, 89.1% of tirzepatide 15 mg participants achieved at least 5% weight loss versus 34.4% on placebo [15]
Expired Semaglutide : Avoid using expired Semaglutide, as it may lose effectiveness and pose health risks
A person chasing the broader insulin-sensitivity/stress-signaling mechanism, injectable, with the endogenous-origin asterisk, lands on MOTS-c
They also are changing how people shop for groceries
Learn more about our comprehensive medical weight loss programs or explore our weight loss medication guide
Observational studies supported these findings, indicating fewer alcohol-related healthcare events among GLP-1 RA users compared to non-users or those on alternative treatments